Graduated from Academy of Sciences and received a Ph.D. degree in organic synthesis. Successively served as project leader, project manager, and head of the synthesis department in Lunan Pharmaceutical, Jumpcan Pharmaceutical, and Suzhong Pharmaceutical, mainly engaged in small molecule drug design and synthesis, drug process development, etc., participated in and responsible for many projects which has obtained clinical approvals and production approvals, and has rich experience in drug development. In April 2021, he served as the head of R&D department of Anqing Roundcare Pharmaceutical. Many papers and patents have been published.

Academic and Work Career:
Nov 2013 – Present: Lecturer, School of Bioengineering, Qilu University of Technology
Dec 2010 – Oct 2013: Postdoctoral Researcher, Department of Environmental Science and Engineering, Tianjin University
Sept 2008 – July 2010: Researcher and Project Leader, New Era Pharmaceutical Company
Sept 2004 – June 2008: Ph.D. in Biomolecular Engineering, Tianjin University
Sept 2001 – July 2004: M.S. in Biochemistry and Molecular Biology, Shenyang Agricultural University
Sept 1996 – July 1999: Associate Degree in Biotechnology, Shenyang Agricultural University
Career Summary:
Dr. Wang began his career at Lunan Pharmaceutical, where he resolved clinical issues related to the "Ganglioside Project" and gained significant expertise in microbial fermentation technology and production management through his work on the daunorubicin project. He later served as Technical Supervisor at Zhengzhou Tuoxin Biotech, focusing on environmental microbiology. There, he successfully developed an enzymatic method for chiral resolution of S-2-chloromandelic acid and optimized the fermentation process of Streptococcus equi.
During his postdoctoral tenure at Tianjin University, Dr. Wang concentrated on environmental and industrial microbiology, where he conducted transcriptome profiling of aflatoxin-induced liver cancer and enhanced the production of teicoplanin through strain engineering. Following this, at Qilu University of Technology, his research has centered on metabolic engineering and synthetic biology, where he built several yeast-based cell factories that significantly improved heterologous protein expression. He also supervised the successful graduation of master's students under his mentorship.
Currently, Dr. Wang is engaged in synthetic biology research at Anqing Longkun Pharmaceutical, having made significant progress in the biocatalysis of sitagliptin and the strain construction for the production of intermediates for COVID-19 therapies, as well as the rational design of transaminases for regorafenib synthesis, demonstrating his exceptional capabilities in both research and industrial application.

With over a decade of experience as a senior researcher in drug synthesis at a large pharmaceutical company, Rao Jingwei leads the selection and execution of new drug projects at Roundcare. He spearheads innovative drug research tasks, directs experimental activities, and plays a key role in developing the processes and compiling the registration data for generic drugs, all with the goal of expediting the market entry of both innovative and first-to-market generic drugs. He has successfully advanced the development and implementation of industrial-scale production lines with competitive advantages. Rao possesses deep knowledge of reaction mechanisms and impurity research, coupled with extensive hands-on experience. His expertise extends to effective team and project management.